|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Transarterial chemoembolization (TACE) in patients with liver metastases of breast cancer: what we can?статья
- Авторы: Kit O.I., Vladimirova L.Iu, Shatova Iu S., Chernyk M.N., Snezshko T.A., Popova I.L., Mezencev S.S.
- Журнал: Tumori
- Том: 105
- Номер: 1_suppl
- Год издания: 2019
- Издательство: II Pensiero Scientifico Editore srl
- Местоположение издательства: Italy
- Первая страница: 13
- Последняя страница: 13
- DOI: 10.1177/0300891619826184
- Аннотация: Introduction: Metastatic breast cancer requires systemic therapy in most of cases but the local therapy can be used as well. The aim of this study was to determine the response and OS rates in patients with liver metastases of breast cancer who undergo TACE in combination with chemotherapy. Materials and methods: Open-label prospective non-ran- domized single-center study was performed. 60 patients had history of histologically confirmed breast cancer and histologically and/or radiographically confirmed liver metastases. 26 patients (group 1) received chemotherapy and 34 patients (group 2) who had 1-2 TACE procedures (doxorubicin 30 mg/m2, 5-fluorouracil 600 mg/m2, 10 ml of Lipiodol and 300-500 μm Microsphere HepaSphere) fol- lowing chemotherapy (taxane-contained regimes) with PR/ SD as a result of treatment. Exclusion criteria: 70% damage of the hepatic parenchyma, partial or complete main portal vein thrombosis, comorbidity in decompensating, contrain- dications for the angiography and selective visceral cathe- terization. The groups were comparable according the main clinical characteristics: the age, primary stage, biological subtype and previous treatment (p>0,05). Results: Response was assessed according RECIST by MRI. PR – 7 (20,6%), SD – 23 (67,6%), PD – 4 (11,8%). Side effects of TACE: nausea/vomiting Gd1 – 8 patients (23,5%), stomach cramps Gd1– 3 patients (8,8%). Median follow-up was 17 months. The Kaplan–Meier-estimation of the 3-year OS for the 1 group – 63,2%, for the 2 group - 43,8% (p=0,039). Conclusion: TACE can be included to the treatment proto- col of the patients with liver metastases of breast cancer with partial response/stable disease following chemother- apy for further consolidation.
- Добавил в систему: Владимирова Любовь Юрьевна